share_log

Syndax Pharmaceuticals Received FDA Orphan Drug Designation on Wednesday for axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

Syndax Pharmaceuticals Received FDA Orphan Drug Designation on Wednesday for axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

Syndax制药公司周三获得FDA孤儿药物称号，用于治疗特发性肺纤维化的Aaxatilimab
Benzinga Real-time News ·  2021/04/08 17:23

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=807821

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=807821

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发